Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck and Co Inc | 541 |
| 2 | Johnson and Johnson | 502 |
| 3 | AbbVie Inc | 452 |
| 4 | Roche Holding AG | 309 |
| 5 | Alcon Inc | 298 |
| 6 | Theravance Biopharma Inc | 266 |
| 7 | Purdue Pharma LP | 239 |
| 8 | Euro Celtique SA | 206 |
| 9 | AstraZeneca PLC | 202 |
| 10 | Pfizer Inc | 201 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 10,381 |
| 2 | A61K | Medicinal preparations | 9,467 |
| 3 | C07D | Heterocyclic compounds | 4,571 |
| 4 | C07K | Peptides | 1,459 |
| 5 | A61F | 1,412 |
| 6 | C07C | Acyclic and carbocyclic compounds | 1,210 |
| 7 | A61M | Devices for introducing media into the body | 803 |
| 8 | C12N | Microorganisms, enzymes | 768 |
| 9 | G01N | Investigating / analysing materials | 731 |
| 10 | A61L | Sterilising / disinfecting materials | 639 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Application of the Levobunolol Hydrochorid in preparing medicament for resisting Eimeria tenella | 2018 | 2 | |
| Indole beta-site alkylation method without participation of transition metal | 2021 | 1 | |
| Preparation method of levobunolol hydrochloride | 2021 | Hangzhou Normal University | 0 |
| A kind of preparation method of Levobunolol Hydrochorid | 2019 | Hangzhou Normal University | 0 |
| Instant gel rubber of levobunolol hcl for eyes | 2009 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 2 |
| 2017 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Gary D. Novack | University of California, Irvine | 27 |
| 2 | Elaine P. Kelley | Allergan (United States) | 9 |
| 3 | Franz-Josef Leinweber | Wake Forest University | 6 |
| 4 | Hideaki Kohri | Otsuka (Japan) | 5 |
| 5 | Kwou‐Yeung Wu | Kaohsiung Medical University | 5 |
| 6 | M. Ober | Praxis für Humangenetik | 4 |
| 7 | Hwei‐Zu Wang | Kaohsiung Medical University Chung-Ho Memorial Hospital | 4 |
| 8 | Seiji Morita | Otsuka (Japan) | 4 |
| 9 | Charles F. Schwender | 4 | |
| 10 | KAZUYUKI NAKAGAWA | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Test-retest reliability of the CSV-1000 contrast test and its relationship to glaucoma therapy. | 1994 | 189 | Glaucoma and retinal disorders |
| Extracapsular cataract extraction with posterior chamber lens implantation in primary angle-closure glaucoma | 1997 | 97 | Glaucoma and retinal disorders |
| Intraocular pressure rise after phacoemulsification with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience. | 1995 | 83 | Glaucoma and retinal disorders |
| Allergic reactions to brimonidine in patients treated for glaucoma | 2002 | 65 | Glaucoma and retinal disorders |
| Correlates of acute exercise-induced ocular hypotension. | 1994 | 63 | Glaucoma and retinal disorders |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of levobunolol?
Which companies hold the most patents related to levobunolol?
What is the patent filing trend for levobunolol-related inventions in recent years?
What are the primary research topics associated with levobunolol in academic literature?
Which patent classifications dominate levobunolol-related filings?